Attenuation of Cocaine’s Reinforcing and Discriminative Stimulus Effects via Muscarinic M_1 Acetylcholine Receptor Stimulation

Morgane Thomsen, P. Jeffrey Conn, Craig Lindsley, Jürgen Wess, Joon Y. Boon, Brian S. Fulton, Anders Fink-Jensen, and S. Barak Caine

Alcohol and Drug Abuse Research Center, McLean Hospital/Harvard Medical School, Belmont, Massachusetts (M.T., J.Y.B., B.S.F., S.B.C.); Vanderbilt Program in Drug Discovery, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (P.J.C., C.L.); Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland (J.W.); and Laboratory of Neuropsychiatry, University of Copenhagen and Psychiatric Center Rigshospitalet, Copenhagen University Hospitals, Copenhagen, Denmark (A.F.-J.)

Received September 25, 2009; accepted December 7, 2009

ABSTRACT

Muscarinic cholinergic receptors modulate dopaminergic function in brain pathways thought to mediate cocaine’s abuse-related effects. Here, we sought to confirm and extend in the mouse species findings that nonselective muscarinic receptor antagonists can enhance cocaine’s discriminative stimulus. More importantly, we tested the hypothesis that muscarinic receptor agonists with varied receptor subtype selectivity can blunt cocaine’s discriminative stimulus and reinforcing effects; we hypothesized a critical role for the M_1 and/or M_4 receptor subtypes in this modulation. Mice were trained to discriminate cocaine from saline, or to self-administer intravenous cocaine chronically. The nonselective muscarinic receptor antagonists scopolamine and methylscopolamine, the selective muscarinic agonists oxotremorine and pilocarpine, the M_1/M_4-prefering agonist xanomeline, the putative M_2 selective agonist (4-hydroxy-2-butylnyl)-1-trimethylammonium-3-chlorocarbanilate chloride (McN-A-343), and the novel M_1-selective agonist 1-(1-(2-methylbenzyl)-1,4-bipiperidin-4-yl)-1H benzo[d]imidazol-2(3H)-one (TBPB) were tested as substitution and/or pretreatment to cocaine. Both muscarinic antagonists partially substituted for cocaine and enhanced its discriminative stimulus. Conversely, muscarinic agonists blunted cocaine discrimination and abolished cocaine self-administration with varying effects on food-maintained behavior. Specifically, increasing selectivity for the M_1 subtype (oxotremorine < xenomeline < TBPB) conferred lesser nonspecific rate-suppressing effects, with no rate suppression for TBPB. In mutant mice lacking M_1 and M_4 receptors, xanomeline failed to diminish cocaine discrimination while rate-decreasing effects were intact. Our data suggest that central M_1 receptor activation attenuates cocaine’s abuse-related effects, whereas non-M_1/M_4 receptors probably contribute to undesirable effects of muscarinic stimulation. These data provide the first demonstration of anticocaine effects of systematically applied, M_1 receptor agonists and suggest the possibility of a new approach to pharmacotherapy for cocaine addiction.

Cocaine and other stimulant abuse is a considerable public health problem, for which no established pharmacotherapy is available. Mounting evidence suggests that cholinergic systems are implicated in abuse-related effects of cocaine and other abused drugs. The reinforcing effects of cocaine depend on dopamine systems that arise in the ventral tegmental area (VTA) and project to the nucleus accumbens (NAc; Robbins et al., 1980). Dopamine release in these pathways is regulated by cholinergic input through muscarinic receptors (Oakman et al., 1995; Blaha et al., 1996). In addition, muscarinic receptors within the striatum (including the NAc) colocalize with dopamine receptors and modulate neuronal responses to dopamine receptor activation. Specifically, M_4 and D_1 receptors exert directly opposing effects on cyclic AMP synthesis, whereas M_1 receptors oppose the effects of D_2 receptors (Di Chiara et al., 1994; Onali and Olianas, 2002). Systemic administration of muscarinic antagonists induces striatal dopamine release in humans and rats, and was found to potentiate cocaine-induced dopamine increases.
in rats (Dewey et al., 1993; Chapman et al., 1997; Tanda et al., 2007). Conversely, muscarinic agonists produce functional dopamine antagonism (Bymaster et al., 1998). Based on the above-mentioned interactions with dopamine receptors, the M₁ and M₅ receptors seem most likely to mediate this functional dopamine antagonism. Most studies investigating the effects of cholinergic manipulations on rewarded behaviors have focused on the roles of specific brain regions, rather than on systemic pharmacological manipulations. In rats, immunotoxic destruction of cholinergic neurons in the NAc increased the potency of self-administered cocaine, whereas intra-NAc-infused exotremoline, a muscarinic agonist, reduced cocaine self-administration (Smith et al., 2004; Mark et al., 2006). Those findings indicate that stimulation of NAc muscarinic receptors opposes the reinforcing effects of cocaine. In contrast to the NAc, the nonselective cholinergic agonist carbachol produced conditioned place preference and was self-administered when infused into the VTA (Ikemoto and Wise, 2002). Experimenter-induced elevation of acetylcholine levels in the VTA similarly reinstated lever pressing in rats trained to self-administer cocaine by a mechanism dependent on muscarinic receptors (You et al., 2008). Intra-VTA infusions of muscarinic antagonists opposed cocaine self-administration and blunted its effect on extracellular VTA dopamine (You et al., 2008). Lesions of the pedunculopontine tegmental nucleus were similarly shown to reduce amphetamine reward (Bechara and van der Kooy, 1989; Alderson et al., 2004). Thus, muscarinic receptors in the VTA and pedunculopontine tegmental nucleus seem to facilitate drug reward. Those facilitations most likely depend on M₅ receptors (Forster et al., 2002; Thomsen et al., 2005), although recent studies indicate that M₂ receptors may modulate effects of different drugs of abuse differentially (Schmidt et al., 2010), and other brain regions and muscarinic receptors may also facilitate abuse-related effects of drugs (Crespo et al., 2006; Carri-gan and Dykstra, 2007). Because of the opposing effects of muscarinic receptors in different brain regions, one cannot easily generalize from these studies what effects systemic administration of muscarinic ligands would have. Although studies targeting specific brain sites are important to help us understand the biology of addiction disorders, it is most likely that pharmacotherapy in humans will be given systemically. Most studies investigating the effect of systemically administered muscarinic ligands on behavioral effects of cocaine have focused on antagonists, in general, showing enhancement of cocaine’s effects (Wilson and Schuster, 1973; Acet et al., 1996; Katz et al., 1999; Tanda and Katz, 2007; but see Ranaldi and Woolver-ton, 2002). Few reports have been published on modulation of cocaine’s effects by systemically applied muscarinic agonists or acetylcholinesterase inhibitors. In a single-session tail-vein self-administration procedure in mice, muscarinic agonists decreased rates of cocaine self-administration (Rasmus-sen et al., 2000). However, because the pretreatments were tested against the peak dose of cocaine, it is difficult to ascertain whether this decrease in response rates reflected a leftward or rightward shift in cocaine’s dose-effect function. In addition, nonspecific rate-decreasing effects of the pretreatments could have contributed to those findings. Acetylcholinesterase inhibitor treatment prevented the development of conditioned place preference to both morphine and cocaine and decreased cocaine self-administration (Hikida et al., 2003; Grasing et al., 2009). However, the clinical usefulness of acetylcholinesterase inhibitors and nonselective muscarinic agonists may be limited by opposing effects at different receptor subtypes, and by well recognized adverse effects (e.g., nausea). As a final point, hypercholinergic rats showed a blunted response to cocaine (Fagergren et al., 2005). Here, we tested the hypothesis that systemically administered muscarinic agonists would attenuate the abuse-related effects of cocaine. We further hypothesized that selectivity for M₁ or M₅/M₄ subtypes would confer greater effectiveness and lower risk of adverse effects. We tested various muscarinic ligands, including the novel M₅-selective allosteric agonist TBPB (Jones et al., 2008), in a cocaine discrimination procedure and a chronic cocaine self-administration procedure in mice.

Materials and Methods

Animals and Housing. Male Swiss-Webster mice, male wild-type C57BL/6NTac and male M₁−/−M₅−/− mice were bred at Taconic Farms (Germantown, NY) and were acquired at 4 to 8 weeks of age. M₁−/− and M₅−/− mice were generated as described previously by use of 129S6/SvEv embryonic stem cells (Gomeza et al., 1999; Miyakawa et al., 2001) and backcrossed 11 generations to C57BL/ 6NTac females to produce essentially congenic mice. Double-knockout mice were bred by intercrossing the single-knockout lines and then maintained as a separate line, because of the low yield of double-knockout mice if bred by heterozygous intermating. Age- and sex-matched C57BL/6NTac mice were thus used as wild-type controls. Animals were acclimated to the housing facilities for at least 7 days before experiments were initiated. During this time they were also handled, and they were anesthetized briefly once for subcutaneous implantation of an identification microchip. Animals were kept in a 12-h light/dark cycle at −22°C and −55% humidity and were group housed up to five per cage. Water was accessible ad libutum and standard rodent chow (rodent diet 5001; PMI Feeds, Inc., St. Louis, MO) was provided once daily after training/testing sessions, 4 g/mouse/day. Rodent “treats,” nesting material, and hiding/nesting devices were provided for enrichment. Running wheels were available, although before catheter implantation, only in the self-administration groups, to avoid potential injuries caused by the protruding catheter base. All testing was conducted during the light phase of the circadian cycle. All procedures were carried out in accordance with National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee.

Operant-Conditioning Apparatus. The same type of apparatus was used for drug discrimination and self-administration, but distinct equipment was dedicated to each assay. Operant-conditioning chambers and training and evaluation of food-maintained behavior under a fixed ratio (FR) schedule of reinforcement have previously been described in detail (Thomsen and Caine, 2005). In brief, each operant-conditioning chamber contained two nose-poke holes 10 mm above the grid floor, each equipped with a photocell and a yellow cue light. Centered between the holes was a plate into which liquid food could be delivered. For self-administration, a liquid swivel mounted on a balance arm was used for intravenous drug delivery in the freely moving animals.

Training and Evaluation in Cocaine Discrimination. Mice were trained to discriminate 10 mg/kg cocaine from saline, administered intraperitoneally 10 min before the session. Liquid food (25 μL of Ensure protein drink, vanilla) was used as the reinforcer, with a maximum of 30 reinforcers available per 20-min session. Mice were trained initially under a FR 1 schedule, with the 10-min pretreatment time spent in the home cage, to ensure that the first nose-pokes were reinforced. The FR was then gradually increased to a final FR
10, and longer portions of the pretreatment time were spent in the operant-conditioning chamber. Final sessions were preceded by a 10-min pretreatment period in the chamber, during which all lights were off and responding had no scheduled consequences. Cocaine and saline were presented in pseudorandom order, and mice were counterbalanced with cocaine trained on the left or right hole. Criteria for stable discrimination were met when at least 7 of 8 consecutive sessions satisfied: 1) ≥10 reinforcers earned per session, 2) ≥80% correct responses for the first reinforcer, and 3) ≥80% correct total responses.

After criteria were met, mice were tested with saline and 0.32 to 18 mg/kg cocaine to generate dose-effect functions. In substitution tests, amphetamine (0.1–1.8 mg/kg i.p.), U-50488 (3.2–18 mg/kg i.p.), scopolamine (0.032–56 mg/kg i.p.), or methylscopolamine (1–56 mg/kg i.p.) was administered immediately before placing the animal in the test chamber. For drug combinations, 0.32 mg/kg scopolamine or 1 mg/kg methylscopolamine was added to cocaine solutions of each dose, and administered as substitutions. In pretreatment tests, oxotremorine (0.032–0.18 mg/kg s.c.) was administered 20 min before cocaine, pilocarpine (1–10 mg/kg s.c.) 30 min before cocaine, xanomeline (0.32–3.2 mg/kg s.c.) 15 min before cocaine, McN-A-343 (3.2–18 mg/kg s.c.) immediately before cocaine, and TBPB (18–100 mg/kg i.p.) 30 min before cocaine. For each drug including cocaine, doses were tested within-subjects according to a Latin square design. At least one training session was interspersed between each test session, and tests were only performed when mice satisfied discrimination criteria.

**Training and Evaluation of Cocaine Self-Administration.**

Training and evaluation of food-maintained behavior and cocaine self-administration under a FR 1 schedule have been described elsewhere (Caine et al., 2002; Thomsen and Caine, 2005). Responding in the right-sided hole resulted in delivery of a reinforcer and turning on of the cue light for 20 s during which no reinforcer could be earned (i.e., postreinforcer timeout). Cocaine solutions or saline was delivered in 0.56 ml/kg doses, e.g., for a 32-g mouse, 18 µl infused over 3.2 s. Responses in the left-sided hole were counted but had no scheduled consequences. At the start of sessions, a single noncontingent reinforcer was delivered, then the house light was turned on, and remained illuminated until the end of the session. The mice were initially trained with liquid food (Ensure, vanilla); mice were placed in the operant-conditioning chamber daily for 2-h sessions, 5 days/week. The mice were allowed at least five consecutive sessions to acquire responding, and as long as needed until criteria were met (rarely more than five sessions; criteria: ≥20 reinforcers earned per session, with <20% variation over two sessions and ≥70% active responses) After acquisition criteria were met, water was substituted for at least three sessions and until responding was extinguished to <50% of each mouse’s food-maintained responding.

An indwelling catheter was then implanted into the right or left external jugular vein under oxygen/sevoflurane vapor anesthesia. The surgical procedure has been described in detail previously (Thomsen and Caine, 2005). In brief, a catheter (Silastic tubing 0.2-mm inner diameter, 0.4-mm outer diameter) was inserted 1.2 cm into the jugular vein and delicately anchored to the vein. The catheter ran subcutaneously to the base located above the midsagittal region. The mice were allowed 7 days recovery, during which 0.02 ml of 0.9% saline containing heparin (30 USP units/ml) and antibiotic (cefazolin, 67 mg/ml) were infused daily through the catheter to forestall clotting and infection. After the postoperative recovery period, catheters were flushed with saline containing heparin immediately before and after self-administration sessions, and the free end of the cannula guide was kept closed at all times. Catheter patency was confirmed before initiation of cocaine self-administration and after completion of each dose-effect determination by the infusion of 0.02 to 0.03 ml of 1% brevital in saline. Loss of muscle tone and clear signs of anesthesia within 3 s of infusion indicated catheter patency.

After recovery, mice were again introduced to the operant-conditioning chambers for 3-h sessions, 5 days/week, and allowed to self-administer 1.0 mg/kg infusion cocaine intravenously under the same FR 1 schedule as above. Criteria for stable cocaine self-administration were the same as for food, followed by saline substitution until extinction criteria were met (<50% of cocaine responding). Cocaine dose-effect functions were determined in each mouse according to a Latin square design, 0.032 to 1.0 mg/kg infusion. Then dose-effect functions were determined again in the same manner, but with each session preceded by administration of a muscarinic agonist. In some mice, 3.2 mg/kg/infusion cocaine was tested last, without pretreatment and then with pretreatment. Finally, liquid food was again substituted as the reinforcer for two sessions, first with no pretreatment, then with the same muscarinic agonist tested with cocaine, in each mouse.

**Drugs.**

Cocaine hydrochloride was supplied by the National Institute on Drug Abuse (National Institutes of Health, Bethesda, MD). D-Amphetamine sulfate, scopolamine hydrobromide, (−)-scopolamine methyl bromide (methylscopolamine), oxotremorine mesquinumate, McN-A-343 and SC-etaclopride were purchased from Sigma-Aldrich (St. Louis, MO). Pilocarpine hydrochloride and (−)-U-50488 hydrochloride were purchased from Tocris (Ellisville, MO). TBPB was synthesized at the Vanderbilt University. Xanomeline was synthesized at the McLean Hospital according to previously published methods (Kane et al., 2008). TBPB and U-50488 were dissolved in double-deionized water, and eticlopride was dissolved in ethanol followed by dilution in sterile water (final concentration ethanol, 1%). All other drugs were dissolved in sterile 0.9% saline. All drug doses refer to the weights of the respective salts.

**Data Analysis.**

For the drug discrimination assay, the percentage of drug-appropriate responding (%DAR) for the whole session and total response rates (i.e., responses in both holes combined) are presented. In all cases, comparable effects were observed in %DAR for the first reinforcer (not shown). The common occurrence of missing values for %DAR because of complete suppression of behavior by the test drugs precluded the use of ANOVA on %DAR. Effects were thus analyzed by comparing A50 values in cocaine dose-effect functions with and without the test drug. For A50 calculations, the doses estimated to produce 50% DAR (substitution tests), 50% decrease in DAR (pretreatment tests) and 50% decrease in response rates (all tests), were estimated in each mouse by interpolation of the dose-effect curves, then group means and 95% confidence intervals were calculated. Effects on response rates were analyzed by repeated-measures ANOVA with drug dose as factor. For cocaine self-administration dose-effect functions, data from the first 2 h of the sessions were analyzed and presented. This time frame was chosen based on time course data obtained on the pretreatment drugs by use of a mouse operant rate assay in our laboratory. The numbers of reinforcers earned were compared by use of repeated-measures ANOVA with cocaine dose and pretreatment as factors. Significant effects were followed where appropriate by Bonferroni-corrected two-sided paired-sample t tests. Food reinforcers earned under baseline and pretreatment conditions were compared by two-sided paired-sample t test. Significance level was set at p < 0.05 before the Bonferroni correction.

For isobolographic analysis, the %DAR dose-effect functions for cocaine, scopolamine, and methylscopolamine were fitted by nonlinear regression with use of the equation $E = (E_{max} \times A) / (A + A_{50})$, where $E$ denotes the effect, $A$ the dose, $E_{max}$ the maximal effect achieved by the drug in question, $A_{50}$ the dose estimated to elicit 50% of this maximal effect, and $p$ a factor related to the slope of the curve (Hill coefficient). The individual data for all mice, rather than means, were used for curve fitting, and 95% confidence limits were also obtained. Curve fitting was executed by use of GraphPad Prism v. 4.0 for Mac. The equations were then rearranged to express dose as a function of effect: $A = (E \times A_{50}) / (E_{max} - E)^p$. Thus, the equivalent (equieffective) doses of each drug were calculated, and expected additive DAR values (with 95% confidence limits) were computed by adding the dose of cocaine equivalent to 0.32 mg/kg scopolamine, or 1 mg/kg methylscopolamine, to each dose of cocaine tested, and entering this total dose into the cocaine equation. The 95% confi-
dence limits for each drug (i.e., cocaine and either scopolamine or methylscopolamine) were obtained, but only the largest (most conservative) interval for each data point are reported for brevity.

**Results**

**Baseline Cocaine Discrimination Behavior and Control Tests.** Swiss-Webster mice met criteria for cocaine discrimination after on average 15.1 ± 1.3 weeks (range, 6–31 weeks). Figure 1 shows cocaine dose-effect determinations in all mice from which data are reported in the present investigation. Cocaine produced DAR in a dose-dependent manner, reaching 100% in all mice. Positive and negative controls were established with the psychostimulant amphetamine and the k-agonist U-50488, respectively, as shown in Fig. 1 and Table 1. Amphetamine reached 100% DAR in all mice, whereas no appreciable DAR was observed after U-50488 treatment up to a dose that almost eliminated responding (peak DAR in any subject, 3%). Table 1 shows the doses estimated to produce 50% DAR and 50% reduction in response rate (relative to saline) for each drug.

![Figure 1](https://example.com/figure1.png)

**Fig. 1.** Effects of cocaine, d-amphetamine, and the k-agonist U-50488 in mice trained to discriminate cocaine from saline. Abscissa: drug dose in mg/kg; ’V’ indicates vehicle. Ordinates, percentage cocaine-appropriate responses (top), response rate in responses per second (bottom). Data are means ± S.E.M. Groups sizes: cocaine, n = 30; amphetamine, n = 7; U-50488, n = 6. In the top, exceptions to these group sizes are indicated when some mice failed to respond at the highest drug doses. ***, p < 0.01 versus vehicle.

<table>
<thead>
<tr>
<th>Pretreatment (dose)</th>
<th>A50 DAR</th>
<th>n/n</th>
<th>A50 Rate Reduction</th>
<th>n/n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cocaine</td>
<td>1.96 (1.46–2.64)</td>
<td>29/29</td>
<td>Not calculated</td>
<td>4/29</td>
</tr>
<tr>
<td>Amphetamine</td>
<td>0.33 (0.22–0.54)</td>
<td>7/7</td>
<td>Not calculated</td>
<td>3/7</td>
</tr>
<tr>
<td>U-50488</td>
<td>Not applicable</td>
<td>0/6</td>
<td>9.32 (6.25–13.90)</td>
<td>6/8</td>
</tr>
<tr>
<td>Scopolamine</td>
<td>0.90 (0.29–2.76)</td>
<td>4/8</td>
<td>Not calculated</td>
<td>3/8</td>
</tr>
<tr>
<td>Methylscopolamine</td>
<td>4.46 (2.95–14.15)</td>
<td>6/8</td>
<td>33.13 (20.34–53.95)</td>
<td>5/8</td>
</tr>
</tbody>
</table>

n/n indicates the number of mice showing ±50% reduction in %DAR and ±50% reduction in response rates, respectively, over the number of mice tested.

**Effects of Muscarinic Receptor Antagonists in the Cocaine Discrimination Assay.** As shown in Fig. 2, scopolamine and methylscopolamine both substituted partially for cocaine (scopolamine peak: 44 ± 17% DAR at 3.2 mg/kg; methylscopolamine peak: 63 ± 18% at 32 mg/kg; mean ± S.E.M.). Methylscopolamine was significantly less potent than scopolamine (see Table 1), consistent with its poorer penetration of the blood-brain barrier. Neither drug significantly affected response rate but 56 mg/kg methylscopolamine resulted in the death of the first mice tested, and evaluation of this dose was therefore discontinued.

Figure 3 shows that the addition of 0.32 mg/kg scopolamine to cocaine produced a moderate leftward shift in the dose-effect curve, which was significant based on nonoverlapping 95% confidence intervals for cocaine’s A50 values: cocaine alone, 1.95 (1.19–3.19) mg/kg; cocaine + scopolamine, 0.64 (0.42–0.97) mg/kg. Scopolamine alone at 0.32 mg/kg did not engender any DAR (0–1% in individual mice). Response rate was not significantly affected by either cocaine or scopolamine dose. The addition of 1.0 mg/kg methylscopolamine produced a more pronounced leftward shift, so that a lower cocaine dose was added to enable A50 calculations (0.1 mg/kg, tested last). The effect of methylscopolamine addition was significant based on nonoverlapping 95% confidence intervals for cocaine’s A50 values: cocaine alone, 1.91 (1.12–3.26) mg/kg; cocaine + methylscopolamine, 0.38 (0.18–0.83) mg/kg. Methylscopolamine alone at 1 mg/kg did not engender any appreciable DAR (0–3% in individual mice). Response rate was not significantly affected by either cocaine or methylscopolamine dose.

Table 2 shows the results of isobolographic analysis of the cocaine + scopolamine and the cocaine + methylscopolamine combinations. The calculated dose of cocaine equivalent to 0.32 mg/kg scopolamine was 0.409 mg/kg, 95% confidence limits of 0.003 to 1.207 mg/kg. The calculated dose of cocaine equivalent to 1 mg/kg methylscopolamine was 0.431 mg/kg, 95% confidence limits of 0.007 to 0.754 mg/kg. In both cases, the expected dose-effect curve if simple additivity was assumed did not differ significantly from the experimentally determined cocaine-alone curves (data not shown). In contrast, comparison of cocaine alone with the experimentally determined drug combinations indicated that the combination was significantly more potent than expected for additivity, at least for portions of the curve (see Table 2).

**Effects of Muscarinic Receptor Agonists in the Cocaine Discrimination Assay.** Figure 4 shows the effects on %DAR (top) and response rate (bottom) of pretreatment with the nonselective muscarinic agonists pilocarpine and oxotremorine, the M1/M4-preferring agonist xanomeline, the novel M1-selective agonist TBPA, and the non-brain pene-trant M1 agonist McN-A-343.

Pilocarpine had little effect on %DAR but decreased re-
response rates ($F_{4,32} = 85.9, p < 0.0001$). Oxotremorine produced a 50% decrease in DAR, but also suppressed response rates ($F_{3,24} = 30.9, p < 0.0001$), so that only four mice emitted responses at the highest dose. Of those, two emitted responses only in the cocaine-appropriate hole, and two emitted responses only in the saline-appropriate hole. Potencies for suppression of DAR and response rates are shown in Table 3, significance of post hoc tests on rate are shown in Fig. 4. Xanomeline decreased DAR by up to 60% (peak effect at 1.8 mg/kg), but also suppressed response rates as a function of dose ($F_{4,32} = 21.5, p < 0.0001$). TBPB decreased DAR by 37% at 32 mg/kg, whereas higher doses had little effect on DAR. Pretreatment with dose of TBPB ($F_{4,28} = 9.7, p < 0.0001$). McN-A-343 had little effect on DAR, because only two of nine mice showed decreases at the highest dose. Pretreatment to a range of cocaine doses in those two mice were not indicative of rightward shifts; instead, this pretreatment produced mixed results more consistent with a masking effect or loss of stimulus control (data not shown). Although doses up to 18 mg/kg did not affect response rates significantly, higher doses were not tested because a pilot experiment with 32 mg/kg resulted in lack of responding and/or death in two of four mice tested.

We then assessed whether pretreatment with 0.1 mg/kg oxotremorine, 1.0 or 1.8 mg/kg xanomeline, or 32 mg/kg TBPB could produce a rightward shift in cocaine’s %DAR dose-effect function. Figure 5 shows cocaine dose-effect functions with and without pretreatment (within-subjects). Oxotremorine produced a 3-fold rightward shift, which was not statistically significant based on overlapping 95% confidence intervals (see Table 4). However this dose of oxotremorine suppressed response rates ($F_{1,35} = 58.9, p < 0.0001$) (no significant effect of cocaine dose, no interaction; see Fig. 5 for significant effects post hoc). Xanomeline produced a significant 5- to 7-fold shift in the cocaine DAR curve. Response rates were also decreased by both 1.0 mg/kg xanomeline ($F_{1,25} = 16.1, p < 0.001$) and 1.8 mg/kg xanomeline ($F_{1,35} = 47.5, p < 0.0001$), although decreases reached significance post hoc only at the 1.8 mg/kg pretreatment dose. TBPB produced a comparable rightward shift but did not affect response rates.

To test the hypothesis that the muscarinic agonists attenuated cocaine’s discriminative stimulus by a M1 and/or M4 receptor-dependent mechanism, we tested xanomeline (1.0, 1.8, and 3.2 mg/kg) in knockout mice lacking M1 and M4 receptors. Both wild-type C57BL/6Ntac mice and M1–/–M4–/– mice acquired cocaine discrimination (DAR under saline test, mean ± S.E.M.: wild-type and M1–/–M4–/–, respectively: 1.2 ± 0.6%, 0.5 ± 0.5%; 10 mg/kg cocaine test 99.1 ± 0.3%, 99.4 ± 0.4%; n = 4–9). In the wild-type mice xanomeline decreased DAR similarly to its effects in Swiss-Webster mice, but in the M1–/–M4–/– mice xanomeline had no effect on DAR (Fig. 6). However xanomeline showed similar rate-suppressing effect in wild-type mice ($F_{5,15} = 10.4, p < 0.001$; A90 with 95% confidence limits: 2.36 mg/kg (2.22–2.50)), and in M1–/–M4–/– mice ($F_{5,6} > 100, p < 0.001$; A90 2.48 mg/kg (2.36–2.61)).

We also tested, in Swiss-Webster mice, whether the cocaine-like stimulus produced by a muscarinic antagonist (methylscopolamine) could be blocked by muscarinic agonist pretreatments (oxotremorine, TBPB; Fig. 7). Oxotremorine produced a rightward shift in DAR, and profoundly decreased response rates ($F_{1,28} > 100, p < 0.001$). Post hoc comparisons indicated significant reductions in rate for all
The doses of cocaine needed to produce 30 to 95% DAR in the mouse discrimination assay were calculated from nonlinear curve fitting of the dose-effect functions, both as predicted if cocaine/scopolamine and cocaine/methylscopolamine combinations were additive, and calculated directly from the experimentally determined drug mixture dose-effect functions. Both antagonists enhanced the discriminative stimulus of cocaine in a more-than-additive manner at some effect levels.

**TABLE 2**

Predicted additive and experimentally determined dose of cocaine needed to produce a given effect level in combination with 0.32 mg/kg scopolamine or 1 mg/kg methylscopolamine.

<table>
<thead>
<tr>
<th>Effect Level</th>
<th>Cocaine/Scopolamine Mixture</th>
<th>Cocaine/Methylscopolamine Mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Predicted Additive</td>
<td>Actual</td>
</tr>
<tr>
<td>30</td>
<td>0.88 (0.5–1.36)</td>
<td>0.53 (0.35–0.71)</td>
</tr>
<tr>
<td>40</td>
<td>1.25 (0.79–1.90)</td>
<td>0.63 (0.44–0.86)</td>
</tr>
<tr>
<td>50</td>
<td>1.65 (1.07–2.50)</td>
<td>0.75 (0.54–1.03)**</td>
</tr>
<tr>
<td>80</td>
<td>3.66 (2.32–6.02)</td>
<td>1.32 (0.96–1.90)**</td>
</tr>
<tr>
<td>95</td>
<td>8.90 (4.11–10.0)</td>
<td>2.50 (1.36–3.98)**</td>
</tr>
</tbody>
</table>

* Nonoverlapping 95% confidence limit relative to predicted additive. All doses calculated in mg/kg; effect levels are in %DAR.

**Fig. 4.** Effects of various muscarinic receptor agonists as pretreatment to 10 mg/kg cocaine. Abscissae, muscarinic agonist dose in mg/kg; “V” indicates vehicle. Ordinates, percentage cocaine-appropriate responses (top); response rate in responses per second (bottom). Data are groups means ± S.E.M. Group sizes: TBPB, n = 8; all other, n = 9. Exceptions to these group sizes are indicated when some mice failed to respond at a particular drug dose and were not tested on a higher dose, when applicable. *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus saline.

**TABLE 3**

Pretreatment-induced decreases in DAR and rate, with 10 mg/kg cocaine.

The dose of each pretreatment drug estimated to produce 50% reduction in DAR and the dose estimated to produce 50% reduction in response rate (relative to vehicle) are shown as group mean (95% confidence interval) of values calculated in each mouse. n/n indicates the number of mice showing ≥50% reduction in DAR and ≥50% reduction in response rates, respectively, over number of mice tested (the first n thus represents the number of mice from which A50 values were calculated). Means were not calculated when an A50 could be calculated in less than half the mice tested.

<table>
<thead>
<tr>
<th>Pretreatment Drug</th>
<th>A50 DAR Reduction</th>
<th>n/n (DAR)</th>
<th>A50 Rate Reduction</th>
<th>n/n (Rate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxotremoline</td>
<td>Not calculated</td>
<td>3/9</td>
<td>0.07 (0.05–0.10)</td>
<td>9/9</td>
</tr>
<tr>
<td>Pilocarpine</td>
<td>Not calculated</td>
<td>2/9</td>
<td>4.51 (3.34–6.09)</td>
<td>9/9</td>
</tr>
<tr>
<td>Xanomeline</td>
<td>1.08 (0.78–1.50)</td>
<td>6/9</td>
<td>1.98 (1.59–2.45)</td>
<td>8/9</td>
</tr>
<tr>
<td>TBPB</td>
<td>Not calculated</td>
<td>3/9</td>
<td>67.73 (55.27–83.01)</td>
<td>7/8</td>
</tr>
<tr>
<td>McN-A-343</td>
<td>Not calculated</td>
<td>2/9</td>
<td>0.11 (0.07–0.18)</td>
<td>9/9</td>
</tr>
</tbody>
</table>

**Comparison with Dopamine Antagonist Pretreatment in the Cocaine Discrimination Assay.** As a positive control for the pretreatment effects, we tested the dopamine D2 antagonist eticlopride as pretreatment to cocaine (Fig. 8). Eticlopride decreased DAR by up to 75%, and decreased response rates profoundly in the same dose range (F1,35 = 26.0, p < 0.0001). We then evaluated eticlopride pretreatment, 0.032 and 0.1 mg/kg, over the range of cocaine doses. Both doses of eticlopride produced significant 4- or 5-fold rightward shifts in the DAR curve (see also Table 4). Although the lower dose did not decrease response rate significantly, 0.1 mg/kg did (F1,35 =
Effects of muscarinic agonist pretreatments on the cocaine dose-effect function. Abscisae, cocaine dose in mg/kg; “Sal” indicates saline. Ordinates, percentage cocaine-appropriate responses (top); response rate in responses per second (bottom). Data are group means ± S.E.M. Group sizes: oxotremorine and TBPB, n = 8; xanomeline, n = 9. Exceptions to these group sizes are indicated when some mice failed to respond at a particular drug dose. *p < 0.05; **p < 0.01 versus cocaine alone.

68.3, p < 0.0001), with a significant eticlopride by cocaine interaction (F_{4,35} = 2.8, p < 0.05).

Effects of Muscarinic Receptor Agonists in Cocaine Self-Administration. We also tested muscarinic agonists in mice that intravenously self-administered cocaine chronically. Under baseline conditions, cocaine was self-administered in all three groups of mice with inverted U-formed dose-effect functions typical for the FR 1 schedule of reinforcement. This was confirmed by significant effects of cocaine dose [oxotremorine group (F_{4,20} = 12.0, p < 0.0001), xanomeline group (F_{4,28} = 6.0, p < 0.01), TBPB group (F_{4,28} = 15.3, p < 0.0001)]. In each group, 0.1 and 0.32 mg/kg/infusion cocaine were self-administered above saline levels (p < 0.05–0.01 versus saline; Fig. 9, top). Pretreatment with oxotremorine (0.032 mg/kg), xanomeline (1 mg/kg), or TBPB (32 mg/kg) each abolished cocaine self-administration. Repeated-measures ANOVA confirmed a significant effect of treatment for oxotremorine (F_{1,5} = 15.1, p < 0.05), xanomeline (F_{1,7} = 35.8, p < 0.001), and TBPB (F_{1,7} = 41.7, p < 0.001), as well as significant cocaine dose by pretreatment interactions [(F_{4,20} = 14.7, p < 0.0001), (F_{4,28} = 5.3, p < 0.01), and (F_{4,28} = 9.8, p < 0.0001), respectively]. After agonist pretreatment cocaine did not maintain significant self-administration at any dose.

For comparison, the same mice were tested by use of the same operant procedure reinforced with a palatable liquid food instead of cocaine (Fig. 9, bottom). Oxotremorine decreased food-reinforced responding (p < 0.05), although the magnitude of effect was smaller than for cocaine. Xanomeline produced a small, nonsignificant decrease in food-reinforced behavior (p = 0.15), and TBPB did not affect food-reinforced behavior (p > 0.7). Oxotremorine was also tested at doses of 0.032 and 0.1 mg/kg as pretreatment to a full range of liquid food dilutions in water, using the same methods (see Supplementary Fig. 1). Oxotremorine produced parallel downward shifts in the food concentration-effect curves. ANOVA with food concentration and dose of oxotremorine as repeated-measures factors confirmed an effect of food concentration (F_{4,24} = 36.3, p < 0.0001) and dose of oxotremorine (F_{2,12} = 18.5, p < 0.001), with no interaction.

### Table 4

<table>
<thead>
<tr>
<th>Pretreatment (dose)</th>
<th>A_{50} Cocaine Alone</th>
<th>A_{50} Pretreatment</th>
<th>Fold Shift</th>
<th>Mean Rate Decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxotremorine (0.032)</td>
<td>2.06 (1.30–3.24)</td>
<td>4.92 (2.96–8.16)</td>
<td>3.4 (1.1–5.8)</td>
<td>−53% (−68 to −39%)</td>
</tr>
<tr>
<td>Xanomeline (1.0)</td>
<td>1.22 (0.61–2.44)</td>
<td>5.76 (3.36–9.88)*</td>
<td>5.5 (2.8–8.3)</td>
<td>−28% (−45 to −10%)</td>
</tr>
<tr>
<td>Xanomeline (1.8)</td>
<td>1.16 (0.69–1.94)</td>
<td>5.32 (2.86–9.90)*</td>
<td>7.0 (3.3–11.7)</td>
<td>−51% (−67 to −35%)</td>
</tr>
<tr>
<td>TBPB (32)</td>
<td>1.43 (0.86–2.37)</td>
<td>7.30 (4.04–13.20)*</td>
<td>6.7 (4.3–9.1)</td>
<td>+6% (+15 to +5%)</td>
</tr>
<tr>
<td>Eticlopride (0.032)</td>
<td>1.10 (0.78–1.74)</td>
<td>4.39 (2.70–7.13)*</td>
<td>5.4 (0.9–8.8)</td>
<td>−4% (−9 to +17%)</td>
</tr>
<tr>
<td>Eticlopride (0.1)</td>
<td>1.10 (0.78–1.74)</td>
<td>4.45 (2.15–9.21)*</td>
<td>4.3 (2.6–6.1)</td>
<td>−70% (−87 to −53%)</td>
</tr>
</tbody>
</table>

*Nonoverlapping 95% confidence intervals relative to cocaine alone.
Fig. 7. Effects of muscarinic agonist pretreatments in methylscopolamine substitution. Abscissae, methylscopolamine dose in mg/kg; “Sal” indicates saline. Ordinates, percentage of cocaine-appropriate responses (top); response rate in responses per second (bottom). Data are groups means ± S.E.M. Group sizes (Swiss-Webster mice): oxotremorine, n = 8; TBPB, n = 6. Exceptions to these group sizes are indicated when some mice failed to respond at a particular drug dose. *, p < 0.05; **, p < 0.001 versus methylscopolamine alone.

Discussion

We examined muscarinic modulation of the discriminative and reinforcing effects of cocaine in mice. Swiss-Webster mice readily acquired and maintained cocaine discrimination in a standard two-manipulandum procedure. Control experiments with amphetamine and a κ-agonist confirmed pharmacological specificity of the training stimulus. We found that muscarinic antagonists enhanced, and muscarinic agonists decreased, the discriminative stimulus of cocaine in a manner consistent with involvement of M1 receptors.

Our findings with scopolamine and methylscopolamine confirm and extend previous studies in rats, in which atropine and scopolamine produced leftward shifts in cocaine’s discriminative stimulus (Acri et al., 1996; Katz et al., 1999; Tanda and Katz, 2007). In male Sprague-Dawley rats trained to discriminate 10 mg/kg cocaine from saline, muscarinic antagonists produced little or no cocaine-appropriate responding (Katz et al., 1999; Tanda and Katz, 2007), or partial substitution comparable with the present findings (Acri et al., 1996). Thus, rather than a species difference, it seems that subtle differences using comparable assays (e.g., behavioral or pharmacological history of the subjects) can modify the response to muscarinic antagonists. This is consistent with a weak cocaine-like discriminative stimulus, or a stimulus only partially overlapping with cocaine. Tanda and Katz (2007) showed similar leftward shifts in cocaine discrimination with the M1- or M1/M4-preferring antagonists telenzepine and trihexyphenidyl, and suggested that M1 receptors mediated at least part of those “cocaine-enhancing” effects. Telenzepine and trihexyphenidyl also increased cocaine-induced increases in extracellular NAc dopamine, providing some clues as to the mechanism of this modulation (Tanda et al., 2007). Consistent with this finding, the lower potency of methylscopolamine relative to scopolamine in the present investigation suggests a centrally mediated cocaine-like stimulus of the muscarinic antagonists. Our data also suggested a more-than-additive effect of combining muscarinic antagonists with cocaine. This is consistent with observations of increased effects of cocaine in the absence of appreciable effects of the antagonists alone in some previous studies (Katz et al., 1999; Tanda and Katz, 2007; Tanda et al., 2007).

To the best of our knowledge, modulation of cocaine’s discriminative stimulus by muscarinic agonists has not been described previously. In the present study, oxotremorine produced some reduction in DAR, but only at doses that dramatically decreased response rates. Pilocarpine seemed to have little effect on DAR up to doses that eliminated responding. The rate-suppressing effects of both drugs make it difficult to evaluate any effect on DAR, so that the apparent difference in effects between oxotremorine and pilocarpine may not be reproducible or biologically meaningful. Alternatively, the observed results could reflect differences between the two drugs’ relative efficacies to activate muscarinic receptor subtypes, as several investigations indicated (e.g., Leiber et al., 1990). The putative non-brain-penetrant M1 agonist McN-A-343 had little effect on DAR, up to doses approaching toxicity.
The selectivity of McN-A-343 has been debated, but recent data using muscarinic M₁−/− mice supported the notion that McN-A-343 is functionally selective for the M₁ receptor in vivo (Hardouin et al., 2002; Kremin et al., 2006). McN-A-343 is a quaternary ammonium structure, thought to penetrate the blood-brain barrier poorly (Walland et al., 1997). Although it cannot be excluded that higher doses may have affected DAR, a pilot experiment indicated that a quarter log increase above the highest dose tested would be lethal in some mice, which is consistent with observations in guinea pigs (Walland et al., 1997). Thus, as with the muscarinic antagonists, the relative lack of effect of McN-A-343 on DAR is consistent with a centrally mediated effect of the muscarinic agonists on cocaine discrimination.

The M₁/M₄-preferring agonist xanomeline produced clear shifts in the cocaine discrimination curve, at doses that produced low to moderate rate suppression. The novel M₁-selective agonist TBPB produced a comparable rightward shift at a dose that did not affect response rate. Thus, M₁ receptor stimulation seems sufficient to attenuate cocaine's discriminative stimulus. This finding is also in agreement with the recent finding that TBPB can attenuate amphetamine-induced locomotor stimulation (Jones et al., 2008). It is noteworthy that TBPB lost its effectiveness at higher doses in the present study, presumably because of some antagonist activity at muscarinic non-M₁ receptors (unpublished observations), suggesting a possible contribution of other subtypes in “anticocaine” effects. Further supporting the role of M₁/M₄ receptors in mediating these “anticocaine” effects, xanomeline failed to decrease DAR in the M₁−/−M₄−/− double-knockout mice up to a dose that nearly eliminated responding. It is noteworthy that xanomeline decreased response rates comparably in both genotypes, indicating that rate-decreasing effects were mediated through non-M₁/M₄ muscarinic receptors. Xanomeline has moderate functional selectivity for M₁/M₄ subtypes over M₂/M₃ subtypes, which are the primary subtypes in peripheral tissues (Shannon et al., 1994; Eglen, 2006). We speculate that M₂ and/or M₃ receptor stimulation accounts for most of the rate suppression observed with less selective muscarinic agonists, and that selective M₁ or M₁/M₄ agonists may have a low incidence of side effects typically associated with nonselective muscarinic agonists in humans.

For comparison with the muscarinic agonists, we tested the dopamine D₂ receptor antagonist eticlopride in the cocaine discrimination assay. Eticlopride dose-dependently reduced DAR and produced rightward shifts in the cocaine dose-effect function, as seen previously in monkeys (Spealman, 1996). The magnitude of shift in cocaine DAR was comparable with that obtained with xanomeline and TBPB, up to a dose of eticlopride that almost eliminated responding when tested alone. Some mutual antagonism was apparent, as might be expected, as increasing doses of cocaine attenuated the rate-suppressing effects of eticlopride, up to a certain point. To our knowledge, the muscarinic agonists therefore produced as large an effect in the cocaine discrimination assay as any other pharmacological manipulation reported. We also verified that muscarinic agonists could attenuate the cocaine-like stimulus induced by a muscarinic antagonist, suggesting a common (reciprocal) mechanism of action for muscarinic manipulations enhancing and antagonizing the discriminative stimulus of cocaine, such as modulation of cocaine-induced increases in extracellular dopamine (see above, and Tanda and Katz, 2007).

In addition to cocaine’s discriminative stimulus, we assessed whether muscarinic agonists could blunt the reinforc-
Thomsen et al.

ing effects of cocaine by testing them in mice that intrave-
nously self-administered cocaine chronically. We found that
treatment with oxotremorine, xanomeline, or TBPB abol-
ished cocaine self-administration. Thus, the muscarinic ago-
nists blocked the reinforcing effects of cocaine more com-
pletely than they affected its discriminative stimulus.

Although oxotremorine also decreased food-maintained re-
sponding, xanomeline had little or no effect on food-maintained behavior under the conditions studied. Although the differ-
ece in baseline rates of responding maintained by food
somewhat limits the conclusions that can be drawn from this
comparison, experiments with lower food reinforcer magni-
des suggested that oxotremorine’s effects on operant be-
behavior did not depend on ongoing rates of responding. In
a previous report, intra-NAc-infused oxotremorine reduced
cocaine self-administration in rats but had no appreciable ef-
fect on food-maintained behavior (Mark et al., 2006). This
effect was blocked by the M1-preferring antagonist pirenze-
epine (Mark et al., 2006). Our findings extend those results in
that systemically administered oxotremorine similarly re-
duced cocaine self-administration, but also produced nonspe-
cific rate suppression. Taken together, previous and present
findings suggest two things. First, stimulation of M1 recep-
tors in the NAc (with or without participation of M4 recep-
tors) accounts for most or all of the muscarinic agonist-
induced suppression of abuse-related effects of cocaine.
Second, these effects can be observed in the absence of un-
derirable nonspecific effects by use of M4-selective ligands.

TBPB has moderate affinity for D2 receptors (Jones et al.,
2008), raising the concern that its effects might result from
D2 receptor blockade. However, 100 mg/kg TBPB showed no
D2 occupancy in a positron emission tomography study in
rats (Jones et al., 2008), and oxotremorine and xanomeline
have no or low dopamine receptor affinities (Burt et al.,
1975; Shannon et al., 1994). Furthermore, results of the knockout
and drug administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists.

References

Acri JB, Siedleck BK, and Witkin JM (1996) Effects of benzotropine on behavioral and
toxic effects of cocaine: comparison with atropine and the selective dopamine
uptake inhibitor 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-propyl)-piperazine. J
Pharmacol Exp Ther 277:1163–1171.


brain-stem output of the limbic system critical for the conditioned place prefer-

Modulation of dopamine efflux in the nucleus accumbens after cholin-
nergic stimulation of the ventral tegmental area in intact, pedunculopontine teg-
mental nucleus-lesioned, and laterodorsal tegmental nucleus-lesioned rats. J

Burt DR, Enna SJ, Creese I, and Snyder SH (1975) Dopamine receptor binding in

Bymaster FP, Shannon HE, Rasmussen K, Delapp NW, Mitch CH, Ward JS, Calili-
antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)-6-(3-
propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane. Eur J Pharmacol 356:
109–119.

Caine SB, Negus SS, Mello NK, Patel S, Bristow L, Kulagowski J, Vallone D, Saiardi
A, and Borrelli E (2002) Role of dopamine D2-like receptors in cocaine self-
administration: studies with D2 receptor mutant mice and novel D2 receptor

Carrigan KA and Dykstra LA (2007) Behavioral effects of morphine and cocaine in
M1 muscarinic acetylcholine receptor-deficient mice. Psychopharmacology (Bery)

Chapman CA, Yeomans JS, Blaha CD, and Blackburn JR (1997) Increased striatal
dopamine release measured with positron emission tomography in normal human

Di Chiara G, Morelli M, and Consolo S (1994) Modular functions of neurotrans-
mitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 17:
224–233.

Eglen RM (2006) Muscarinic receptor subtypes in neuronal and non-neuronal cho-

Fagergren P, Ovesen FD, Gein GM, and Hardouin SN (2005) Blunted response to
cocaine in the Flanders hypercholinergic animal model of depression. Neuroscience
132:1159–1171.

are required for prolonged acumbal dopamine release after electrical stimulation

Gomez J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, Shannon H, Xia
locomotor stimulation in M5 muscarinic acetylcholine receptor knockout mice. Proc

behavior following treatment with the cholinesterase inhibitor tacrine in rats
178.

Hardouin SN, Richmond KN, Zimmerman A, Hamilton SE, Feigl EO, and

Acknowledgments

We thank Jennifer Dohrmann and Dana Angood for technical assistance and
Dr. Carrie K. Jones for help with coordination between sites.

Address correspondence to: Dr. Morgane Thomsen, Alcohol and Drug Abuse Research Center, McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478. E-mail mthomsen@mclean.harvard.edu
Supplemental Figure 1

Effects of oxotremorine on operant behavior maintained by liquid food.
Abscissa: % concentration liquid food in water, “W” designated water. Ordinates: number of food reinforcers earned per 2-hr session. Data are groups means ± sem. Groups size: cocaine: N = 7.